Skip to main content

Advertisement

SpringerLink
Log in

The Circulating Proangiogenic Factors CYR61 (CCN1) and NOV (CCN3) Are Significantly Decreased in Placentae and Sera of Preeclamptic Patients

  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

It is thought that preeclampsia results from a shallow invasion of the extravillous trophoblast into the decidua and maternal vessels, which in turn leads to hypoxia and uteroplacental insufficiency. Here, the authors focus on the expression of the proangiogenic secreted molecules CYR61 (CCN1) and NOV (CCN3) in human placentae during normal pregnancy compared with preeclamptic placentae. CYR61 and NOV are strongly expressed in endothelial cells as well as in the extravillous trophoblast, with increasing levels during placental development. Interestingly, the authors found significantly decreased levels in early preeclamptic placentae compared with matched controls. Whereas both CYR61 and NOV proteins are present at constant high levels in the sera of nonpregnant and pregnant women, in the sera of patients with early-onset preeclampsia, levels were significantly reduced. The authors suggest that the reduction of both CCN molecules in preeclampsia could be 1 reason underlying the failure of uterine vascular remodeling. Moreover, their low maternal serum levels could serve as biomarkers for early diagnosis of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Myatt L. Role of placenta in preeclampsia. Endocrine. 2002;19(1):103–111.

    Article  CAS  Google Scholar 

  2. Bdolah Y, Karumanchi SA, Sachs BP Recent advances in understanding of preeclampsia. Croat Med J.2005;46(5):728–736.

    PubMed  Google Scholar 

  3. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799.

    Article  Google Scholar 

  4. Redman CW, Sargent IL Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–1594.

    Article  CAS  Google Scholar 

  5. Schmidt M, Gellhaus A, Kasimir-Bauer S, et al. Angiogenic factors during pregnancy: indicators of preeclampsia. Geburtshilfe und Frauenheilkunde. 2007;67:217–227.

    Article  Google Scholar 

  6. Zhou Y, Damsky CH, Chiu K, et al. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest. 1993;91(3):950–960.

    Article  CAS  Google Scholar 

  7. Lim KH, Zhou Y, Janatpour M, et al. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol. 1997;151(6):1809–1818.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160(4):1405–1423.

    Article  CAS  Google Scholar 

  9. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.

    Article  CAS  Google Scholar 

  10. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6):642–649.

    Article  CAS  Google Scholar 

  11. Mo FE, Muntean AG, Chen CC, et al. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol. 2002;22(24):8709–8720.

    Article  CAS  Google Scholar 

  12. Gellhaus A, Schmidt M, Dunk C, et al. Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. Mol Hum Reprod. 2006;12(6):389–399.

    Article  CAS  Google Scholar 

  13. Rachal AW, Brigstock DR Structural and functional properties of CCN proteins. Vitam Horm. 2005;70:69–103.

    Article  Google Scholar 

  14. Kubota S, Takigawa M. CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis. 2007;10(1):1–11.

    Article  CAS  Google Scholar 

  15. Leu SJ, Lam SC, Lau LF Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins αvβ3 and α6β1 in human umbilical vein endothelial cells. J Biol Chem. 2002; 277(48):46248–46255.

    Article  CAS  Google Scholar 

  16. Lin CG, Leu SJ, Chen N, et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem. 2003;278(26):24200–24208.

    Article  CAS  Google Scholar 

  17. Benirschke K, Kaufmann P, eds. Pathology of the Human Placenta. 4th ed. New York, NY: Springer-Verlag; 2000.

    Google Scholar 

  18. Roberts JM, Redman CW Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341(8858):1447–1451.

    Article  CAS  Google Scholar 

  19. Gellhaus A, Dong X, Propson S, et al. Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells. J Biol Chem. 2004;279(35): 36931–36942.

    Article  CAS  Google Scholar 

  20. Chevalier G, Yeger H, Martinerie C, et al. novH: differential expression in developing kidney and Wilm’s tumors. Am J Pathol. 1998; 152(6):1563–1575.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Schutze N, Kunzi-Rapp K, Wagemanns R, et al. Expression, purification, and functional testing of recombinant CYR61/CCN1. Protein Expr Purif. 2005;42(1):219–225.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Anatomy, University Hospital Essen, Hufelandstr 55, 45122, Essen, Germany

    Alexandra Gellhaus PhD & Elke Winterhager PhD

  2. Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany

    Markus Schmidt MD

  3. Department of Obstetrics and Gynecology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada

    Caroline Dunk PhD & Stephen J. Lye PhD

Authors
  1. Alexandra Gellhaus PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Schmidt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline Dunk PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen J. Lye PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elke Winterhager PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra Gellhaus PhD.

Additional information

Contract grant sponsor: German Research Foundation (DFG), grants Wi 774/21-2 and Wi 774/22-1.We thank Eva Kusch, Georgia Rauter, Gabriele Sehn, Gisela Koestner, and Dr Ljiljana Petkovic for excellent technical assistance. We are also indebted to B. Perbal and N. Schuetze for providing us with NOV and CYR61 antibodies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gellhaus, A., Schmidt, M., Dunk, C. et al. The Circulating Proangiogenic Factors CYR61 (CCN1) and NOV (CCN3) Are Significantly Decreased in Placentae and Sera of Preeclamptic Patients. Reprod. Sci. 14 (Suppl 8), 46–52 (2007). https://doi.org/10.1177/1933719107309816

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719107309816

Keywords

Search

Navigation